Simone Beretta, MD, PhD, Università degli Studi di MilanoBicocca, Milan, Italy, discusses the SUPERCAT trial, which is investigating dual antiglutamate therapy in superrefractory status epilepticus after cardiac arrest. The SUPERCAT protocol combines ketamine and perampanel to block NMDA and AMPA receptors, significantly improving outcomes for patients. This multicenter retrospective study shows a resolution rate of about 80% compared to 40% with other treatments. This interview took place at the 15th European Epilepsy Congress (EEC) 2024 in Rome, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.